Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The shutdown began in late March in the Pacific nation of about 5 million, and a state of national emergency was declared to stifle local transmissions of the respiratory disease. “No one goes home, everyone goes into a managed facility,” Prime Minister Jacinda Ardern said, adding that 14 days spent in a government-approved facility would be a prerequisite for all foreign travellers. “Even one person slipping through the cracks and bringing the virus in can see an explosion in cases, as we have observed with some of our bigger clusters,” she told a media briefing in Wellington on Thursday. Ardern added that her cabinet would decide whether to extend the nationwide curbs on April 20, two days before the lockdown is set to end. The lockdown has reduced domestic transmissions, authorities said, with a steady fall this week in the daily rise in infections. The tally of infections rose by 29 to stand at 1,239 on Thursday, for the lowest daily rise since March 21, a sign the epidemic could be on the retreat since the lockdown began 15 days ago. Overnight, 35 people were declared to have recovered. New Zealand, like neighbouring Australia, has fewer infections than many countries and the pace of infections in both nations has slowed dramatically in the past week. Despite some signs of a plateau in infections, the government said it had no plans to relax the curbs over the Easter weekend and warned of hefty fines for non-essential travel then. Police will step up activity around holiday spots during the Easter holidays, authorities said, with some roadblocks planned. Interactive graphic tracking global spread of coronavirus: open tmsnrt.rs/3aIRuz7 in an external browser.

A: New Zealand orders quarantine for returning citizens in coronavirus battle.
****
Q: Teva Pharmaceutical Industries Ltd’s rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. As with rival PBMs Express Scripts and CVS Health Corp, OptumRx’s lists of covered drugs, or formularies, cover tens of millions of consumers who receive their healthcare from employers and health insurers. About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData. OptumRx’s decision secures easier access to customers for Lilly’s Emgality at all three of the biggest PBMs - including CVS and Express Scripts - and gives Amgen’s Aimovig a leg up after CVS decided not to include it on its preferred drug list. Teva’s Ajovy only has preferred status at CVS, while Amgen also has it at Express Scripts, part of Cigna Corp.  “We are pleased that all three companies have chosen Emgality to be one of the preferred medications, making it accessible to even more patients suffering from migraine,” Lilly said in an emailed statement. Inclusion on a preferred drugs list by the largest PBMs and health insurers is critically important for sales of new medicines. Increasingly, PBMs are choosing a subset of treatments for their coverage list when there are multiple treatments that are considered equivalent. The three treatments, approved by the U.S. Food and Drug Administration last year, belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines. A Teva spokeswoman said the company is committed to increasing access to Ajovy regardless of formulary decisions and is still offering discounts that allow patients to pay nothing in some cases, regardless of insurance. “Since Ajovy injection launched in September, we have experienced strong demand and steady growth, and we continue discussions with payers,” the spokeswoman said. An Amgen spokeswoman said that the company was pleased with the decision and is committed to ensuring affordable access to its drug. Amgen, which shares Aimovig U.S. revenue with Novartis AG, earlier this week reported fourth-quarter sales of $95 million, nearly doubling Wall Street estimates. The OptumRx decision becomes effective Feb. 1. The OptumRx select formulary relegates Teva’s drug to a lower access level that would typically require a higher out-of-pocket cost, it said. PBMs typically extract discounts from drugmakers in return for favorable placement on their preferred list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members. All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect the rebates and discounts to PBMs, who design and negotiate benefits for employers and insurers. All three drugmakers are providing a limited duration supply of the new drugs at no cost directly to patients in addition to other assistance programs. Amgen’s Aimovig was first-to-market from the new class. But the rivals from Teva and Lilly followed soon after. The three large PBMs together cover the majority of the more than 150 million Americans who receive benefits through their employers. Their clients, including insurers and corporations, may choose not to follow a PBM’s recommendations on coverage, but that typically would cost more. Amgen shares were off 28 cents at $186.63, Lilly was up nearly 1 percent at $120.90 and Teva shares traded in New York  were down nearly 1 percent at $19.69.

A: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.
****
Q: The new measures may include screening air travelers for fever when they arrive in the United States from the worst-stricken countries in West Africa, on direct or indirect flights, Schumer said in a statement. He said U.S. Centers for Disease Control and Prevention (CDC) Director Dr. Thomas Frieden told him the agency might adopt some of the recommendations Schumer had made on Ebola screening over the weekend. Those included having the CDC and Customs and Border Protection conduct intense health screening of workers at U.S. ports of entry. The New York Democrat also urged the Department of Homeland Security to create a database of people flying to and from West Africa, which would be shared with hospitals around the country. “The CDC has been doing a very good job thus far in combating the threat, but you can’t be too careful when it comes to stopping a deadly epidemic,” Schumer said in the statement. The outbreak has killed at least 3,439 people out of 7,492 confirmed, probable and suspected cases since it emerged in Guinea in March, in the worst Ebola epidemic on record. Along with Guinea, the worst-hit countries have been Sierra Leone and Ebola. The disease has also spread to Nigeria and Senegal, but is considered contained there. A man who traveled to Dallas from Liberia last week became the first patient diagnosed with the disease on U.S. soil. In Spain, officials reported on Monday that a nurse had become the first person infected with the hemorrhagic virus in Europe. White House spokesman Josh Earnest said the administration had confidence in the system as it exists but was working on additional safety protocols that would be announced in the coming days. “The president’s team is hard at work on developing additional protocols for additional screening measures,” Earnest told reporters on Air Force One.

A:
U.S. to require tougher Ebola screening at airports: senator.
****